GefitinibAcquired drug resistance in EGFR-mutated bone metastasised lung adenocarcinoma: case report

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2019年 / 1778卷 / 1期
关键词：
D O I：
10.1007/s40278-019-71017-8
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：214 / 214
相关论文
共 50 条
  • [41] Osimertinib in EGFR-Mutated Lung Cancer
    Liang, Wenhua
    Zhong, Ran
    He, Jianxing
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (07): : 675 - 675
  • [42] TP53 Loss of Heterozygosity Induces De Novo SCLC Formation in EGFR-Mutated Lung Adenocarcinoma: A Case Report
    Kunimasa, Kei
    Hirotsu, Yosuke
    Amemiya, Kenji
    Nakamura, Harumi
    Nishino, Kazumi
    Honma, Keiichiro
    Okami, Jiro
    Omata, Masao
    Kumagai, Toru
    JTO CLINICAL AND RESEARCH REPORTS, 2022, 3 (05):
  • [43] Case Report: Stevens-Johnson Syndrome and Hepatotoxicity Induced by Osimertinib Sequential to Pembrolizumab in a Patient With EGFR-Mutated Lung Adenocarcinoma
    Gianni, Caterina
    Bronte, Giuseppe
    Delmonte, Angelo
    Burgio, Marco Angelo
    Andrikou, Kalliopi
    Monti, Manlio
    Menna, Cecilia
    Frassineti, Giovanni Luca
    Crino, Lucio
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [44] Implications of EGFR expression in MAPK dependency and adaptive immunity status of EGFR-mutated lung adenocarcinoma
    Torasawa, Masahiro
    Yoshida, Tatsuya
    Shiraishi, Kouya
    Yagishita, Shigehiro
    Uehara, Yuji
    Miyakoshi, Jun
    Higashiyama, Ryoko Inaba
    Mochizuki, Akifumi
    Matsumoto, Yuji
    Shinno, Yuki
    Okuma, Yusuke
    Goto, Yasushi
    Horinouchi, Hidehito
    Hamamoto, Ryuji
    Yamamoto, Noboru
    Watanabe, Shun-ichi
    Yatabe, Yasushi
    Takahashi, Kazuhisa
    Kohno, Takashi
    Ohe, Yuichiro
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [45] Malignant pleural mesothelioma showing rare morphology indistinguishable from myxofibrosarcoma concomitant with EGFR-mutated lung adenocarcinoma: A case report
    Onagi, Hiroko
    Hayashi, Takuo
    Saito, Tsuyoshi
    Kishikawa, Satsuki
    Takamochi, Kazuya
    Suzuki, Kenji
    INTERNATIONAL JOURNAL OF SURGERY CASE REPORTS, 2021, 85
  • [46] Osimertinib in untreated EGFR-mutated advanced lung adenocarcinoma: real world data
    Almusarhed, Manar
    Rehman, Faisal
    Chen, Ryan
    Ahmed, Samreen
    LUNG CANCER, 2023, 178 : S33 - S33
  • [47] mRNA expression profile specific to micropapillary element in EGFR-mutated lung adenocarcinoma
    Koike, Chihiro
    Matsumura, Mai
    Mitsui, Hideaki
    Kataoka, Toshiaki
    Umeda, Shigeaki
    Tateishi, Yoko
    Suzuki, Takehisa
    Arai, Hiromasa
    Okudela, Koji
    CANCER SCIENCE, 2018, 109 : 1409 - 1409
  • [48] Targeted NGS analysis to predict recurrence in resected EGFR-mutated lung adenocarcinoma
    Kim, In Ae
    Kim, Hee Jung
    Hur, Jae Young
    Lee, Seung En
    Park, Jung Hoon
    Lee, Song Am
    Hwang, Jae Jun
    Kim, Wan Seop
    Lee, Kye Young
    CANCER RESEARCH, 2020, 80 (16)
  • [49] Solid Subtype Predicts Early Bone Metastases in Sensitive EGFR-Mutated Lung Adenocarcinoma Patients After Surgery
    Xiong, A.
    Li, C.
    Xu, J.
    Yang, X.
    Nie, W.
    Zhong, H.
    Chu, T.
    Zhang, W.
    Zhong, R.
    Pan, F.
    Shen, Y.
    Lou, Y.
    Zhang, B.
    Han, B.
    Zhang, X.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S966 - S967
  • [50] Solid subtype predicts early bone metastases in sensitive EGFR-mutated lung adenocarcinoma patients after surgery
    Xiong, Anning
    Li, Changhui
    Xu, Jianlin
    Yang, Xiaohua
    Nie, Wei
    Zhong, Hua
    Chu, Tianqing
    Zhang, Wei
    Zhong, Runbo
    Pan, Feng
    Shen, Yinchen
    Lou, Yuqing
    Zhang, Bo
    Han, Baohui
    Zhang, Xueyan
    LUNG CANCER, 2021, 154 : 124 - 130
12345